EPS for Juniper Pharmaceuticals, Inc. (JNP) Expected At $-0.16; Lilly Eli & Co (LLY)’s Sentiment Is 0.89

February 23, 2018 - By Richard Conner

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide. The company has market cap of $81.05 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It currently has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

Analysts expect Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report $-0.16 EPS on March, 6.They anticipate $1.04 EPS change or 118.18% from last quarter’s $0.88 EPS. After having $-0.08 EPS previously, Juniper Pharmaceuticals, Inc.’s analysts see 100.00% EPS growth. The stock decreased 2.91% or $0.25 during the last trading session, reaching $8.35. About 44,478 shares traded. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has declined 42.39% since February 23, 2017 and is downtrending. It has underperformed by 59.09% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 8 selling transactions for $84.24 million activity.

Lilly Endowment Inc holds 100% of its portfolio in Eli Lilly and Company for 123.48 million shares. Private Capital Advisors Inc. owns 388,539 shares or 11.34% of their US portfolio. Moreover, Sector Gamma As has 9.38% invested in the company for 719,546 shares. The California-based Weatherly Asset Management L. P. has invested 7.46% in the stock. Valueworks Llc, a New York-based fund reported 68,125 shares.

Ratings analysis reveals 100% of Eli Lilly’s analysts are positive. Out of 4 Wall Street analysts rating Eli Lilly, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. LLY was included in 4 notes of analysts from September 8, 2016. The company was upgraded on Friday, December 16 by Morgan Stanley. Goldman Sachs upgraded the shares of LLY in report on Tuesday, September 27 to “Buy” rating. Barclays Capital maintained Eli Lilly and Company (NYSE:LLY) on Friday, April 7 with “Overweight” rating. The stock of Eli Lilly and Company (NYSE:LLY) earned “Overweight” rating by JP Morgan on Thursday, September 8.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on April, 24. They expect $1.13 earnings per share, up 15.31% or $0.15 from last year’s $0.98 per share. LLY’s profit will be $1.19B for 17.08 P/E if the $1.13 EPS becomes a reality. After $1.14 actual earnings per share reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts -0.88% negative EPS growth.

The stock decreased 0.46% or $0.36 during the last trading session, reaching $77.19. About 7.69 million shares traded or 71.27% up from the average. Eli Lilly and Company (LLY) has risen 4.70% since February 23, 2017 and is uptrending. It has underperformed by 12.00% the S&P500.

Juniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company has market cap of $90.55 million. The firm develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring technology. It has a 13.38 P/E ratio. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: